Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
154.36B
Market cap154.36B
Price-Earnings ratio
19.76
Price-Earnings ratio19.76
Dividend yield
6.42%
Dividend yield6.42%
Average volume
31.23M
Average volume31.23M
High today
$26.94
High today$26.94
Low today
$26.87
Low today$26.87
Open price
$26.92
Open price$26.92
Volume
2.54M
Volume2.54M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$21.97
52 Week low$21.97

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $26.88. The company's market cap stands at 154.36B, with a P/E ratio of 19.76 and a dividend yield of 6.4%.

During the trading session on 2026-04-28, Pfizer(PFE) shares reached a daily high of $26.94 and a low of $26.87. At a current price of $26.88, the stock is +0.1% higher than the low and still -0.2% under the high.

Trading volume for Pfizer(PFE) stock has reached 2.54M, versus its average volume of 31.23M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $21.97.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $21.97.

PFE News

TipRanks 15m
Pfizer Kept at Hold as Pipeline Uncertainty and LOE Risks Temper Upside, Price Target Cut to $26

Analyst Asad Haider of Goldman Sachs maintained a Hold rating on Pfizer, reducing the price target to $26.00. Claim 55% Off TipRanks Unlock hedge fund-level dat...

Simply Wall St 9h
Pfizer Valuation Check After New Oncology Data And Priority Review For Cancer Regimen

Pfizer (PFE) is back in focus after unveiling extensive new oncology data at the American Society of Clinical Oncology meeting and securing FDA Priority Review...

Pfizer Valuation Check After New Oncology Data And Priority Review For Cancer Regimen
TipRanks 13h
Pfizer Shareholders Reaffirm Leadership, Governance at 2026 Meeting

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

50%

of 30 ratings
Buy
40%
Hold
50%
Sell
10%

More PFE News

24/7 Wall St. 23h
Want $1,188 in Passive Income? Invest $5,000 Into These 3 High-Yielding Stocks

The analyst who called NVIDIA in 2010 just named his top 10 stocks and Conagra Brands wasn't one of them. Get them here FREE . This post may contain links from...

Want $1,188 in Passive Income? Invest $5,000 Into These 3 High-Yielding Stocks
TipRanks 4d
Bristol Myers-Pfizer Alliance launch collaboration with Mark Cuban for Eliquis

The Bristol Myers Squibb-Pfizer (BMY) – Pfizer (PFE) Alliance announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company to offer Eliquis, o...

Simply Wall St 4d
Pfizer Obesity Pipeline Expands As Monthly GLP 1 Candidate Targets Growth

Pfizer (NYSE:PFE) reported positive Phase 2b results for its GLP-1 anti-obesity candidate PF-08653944, targeting once-monthly dosing. The company outlined plan...

Pfizer Obesity Pipeline Expands As Monthly GLP 1 Candidate Targets Growth
TipRanks 5d
Pfizer Advances PF-08653944 Liver Study, Reinforcing Long-Term Pipeline Visibility

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

TipRanks 5d
Pfizer’s New Phase 1 Cancer Trial Adds Quiet Optionality to PFE’s Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

TipRanks 5d
Pfizer Advances Early-Stage Obesity Asset With New Gastric Emptying Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

TipRanks 5d
Pfizer Advances Early-Stage Heart Failure Candidate With Completion of Chinese Phase 1 Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.